ArticleBMC public health2026
Prognostic value of non-invasive fibrosis assessment scores in predicting mortality among individuals with metabolic dysfunction-associated steatotic liver disease.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the prognostic value of nine non-invasive fibrosis scores in predicting all-cause and cardio-cerebrovascular disease (CCD) mortality among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
methodsThis study included 4,377 U.S. adults with MASLD, identified using the NHANES 1999–2018 fasting subsample, with follow-up through December 2019. The nine fibrosis scores evaluated were the non-alcoholic fatty liver disease (NAFLD) fibrosis score, Fibrosis-4 (FIB-4), BARD score, aspartate transaminase-to-platelet ratio index (APRI), Forns score, hepatic steatosis index, NAFLD liver fat score, Steatosis-associated Fibrosis Estimator (SAFE) score, and metabolic dysfunction–associated fibrosis 5 (MAF-5). Kaplan-Meier survival curves, Cox proportional hazards models, and random survival forest (RSF) models were used to assess associations and predictive performance of these scores on mortality outcomes.
resultsThe study cohort had a median age of 52.7 years and was 48.6% male. Over a median follow-up of 8.92 years, 868 deaths occurred, including 289 from CCD. Higher quartiles of fibrosis scores, especially the SAFE score, were significantly associated with elevated mortality risk among individuals with MASLD. Specifically, participants in the highest SAFE score quartile had a 4.4-fold higher risk of all-cause mortality (HR = 4.39, 95% CI: 2.94–6.54) and a 3.9-fold higher risk of CCD mortality (HR = 3.91, 95% CI: 1.69–9.03) compared to those in the lowest quartile. RSF analysis ranked the SAFE score as the most important predictor among the nine fibrosis scores.
conclusionThe SAFE score was the most robust predictor of both all-cause and CCD mortality, highlighting its prognostic utility in MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.